Objective To develop a new evidence‐based, pharmacologic treatment guideline for
rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the …

The treatment and outcomes of patients with rheumatoid arthritis (RA) have been
transformed over the past two decades. Low disease activity and remission are now …

In this article, the 2010 European League against Rheumatism (EULAR) recommendations
for the management of rheumatoid arthritis (RA) with synthetic and biological disease …

This systematic literature review (SLR) regarding the efficacy, duration of use and safety of
glucocorticoids (GCs), was performed to inform the 2022 update of the EULAR …

Background Methotrexate is considered the preferred disease‐modifying anti‐rheumatic
drug (DMARD) for the treatment of rheumatoid arthritis, but controversy exists on the …

Aim To update recommendations based on current best evidence concerning the treatment
of rheumatoid arthritis (RA), focusing particularly on the role of targeted therapies, to inform …

Rheumatoid arthritis (RA) is an aggressive autoimmune arthritis, and current therapies
remain unsatisfactory due to low remission rate and substantially adverse effects. Low-dose …

Objectives To investigate whether baseline disease activity levels and responses in patients
with rheumatoid arthritis (RA) changed during the period 2000–2010. Methods Data were …

Objectives To perform a systematic literature review (SLR) informing the 2016 update of the
recommendations for the management of rheumatoid arthritis (RA). Methods An SLR for the …

Objectives In disease modifying antirheumatic drug (DMARD)-naive early rheumatoid
arthritis (RA), to compare the efficacy of methotrexate (MTX) and infliximab (IFX) with MTX …